title: Impact of pharmacological stress agent on patient motion during rubidium-82 myocardial perfusion PET/CT.
abstract: Patient motion has been demonstrated to have a significant impact on the quality and accuracy of rubidium-82 myocardial perfusion PET/CT. This study aimed to investigate the effect on patient motion of two pharmacological stressing agents, adenosine and regadenoson.
  
  
  
  Dynamic data were retrospectively analyzed in 90 patients undergoing adenosine (n = 30), incremental adenosine (n = 30), or regadenoson (n = 30) rubidium-82 myocardial perfusion PET/CT. Severity of motion was scored qualitatively using a four-point (0-3) scale and quantitatively using frame-to-frame pixel shifts. The type of motion, returning or non-returning, and the frame in which it occurred were also recorded. There were significant differences in both the qualitative and quantitative scores comparing regadenoson to adenosine (P = .025 and P < .001) and incremental adenosine (P = .014, P = .015), respectively. The difference in scores between adenosine and incremental adenosine was not significant. Where motion was present, significantly more adenosine patients were classed as non-returning (P = .018). The median frames for motion occurring were 12 for regadenoson and 14 for both adenosine cohorts.
  
  
  
  The choice of stressing protocol impacts significantly on patient motion. Patients stressed with regadenoson have significantly lower motion scores than those stressed with adenosine, using local protocols. This motion is more likely to be associated with a drift of the heart away from a baseline position, coinciding with the termination of infusion.
authors.affiliation: Nuclear Medicine, Central Manchester University Hospitals, Oxford Road, Manchester, M13 9WL, United Kingdom. Matthew.Memmott@cmft.nhs.uk.
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Memmott
authors.affiliation: Nuclear Medicine, Central Manchester University Hospitals, Oxford Road, Manchester, M13 9WL, United Kingdom.
authors.forename: Christine M
authors.initials: CM
authors.lastname: Tonge
authors.affiliation: Nuclear Medicine, Central Manchester University Hospitals, Oxford Road, Manchester, M13 9WL, United Kingdom.
authors.forename: Kimberley J
authors.initials: KJ
authors.lastname: Saint
authors.affiliation: Nuclear Medicine, Central Manchester University Hospitals, Oxford Road, Manchester, M13 9WL, United Kingdom.
authors.forename: Parthiban
authors.initials: P
authors.lastname: Arumugam
mesh_terms: D000241:Adenosine / Q000494:pharmacology*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003326:Coronary Circulation / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009038:Motion; D055414:Myocardial Perfusion Imaging / Q000379:methods*; D000072078:Positron Emission Tomography Computed Tomography / Q000379:methods*; D011687:Purines / Q000494:pharmacology*; D011720:Pyrazoles / Q000494:pharmacology*; D012119:Respiration / Q000187:drug effects; D012189:Retrospective Studies; D012414:Rubidium Radioisotopes
chemical_list: D011687:Purines; D011720:Pyrazoles; D012414:Rubidium Radioisotopes; C430916:regadenoson; C000615479:Rubidium-82; D000241:Adenosine
keywords: PET/CT imaging; Rubidium-82; patient motion